UB Paderborn / Katalog / Suche / in CDI

Sortiert nach

Einfacher Volltextzugriff von (fast) überall

Installieren Sie die LibKey Nomad-Browsererweiterung und erhalten Sie von vielen Webseiten einfachen Zugriff auf lizenzierte Volltexte oder Open Access Publikationen. Mehr erfahren...

Efficacy and safety of lumacaftor/ivacaftor combination therapy in patients with cystic fibrosis homozygous for Phe508del CFTR by pulmonary function subgroup: a pooled analysis

The lancet respiratory medicine, 2016-08, Vol.4 (8), p.617-626

2016

Volltextzugriff (PDF)

Risk Factors For Rate of Decline in Forced Expiratory Volume in One Second in Children and Adolescents with Cystic Fibrosis

The Journal of pediatrics, 2007-08, Vol.151 (2), p.134-139.e1

2007

Volltextzugriff (PDF)

Association of Socioeconomic Status with the Use of Chronic Therapies and Healthcare Utilization in Children with Cystic Fibrosis

The Journal of pediatrics, 2009-11, Vol.155 (5), p.634-639.e4

2009

Volltextzugriff (PDF)

Improvements in Lung Function and Height among Cohorts of 6-Year-Olds with Cystic Fibrosis from 1994 to 2012

The Journal of pediatrics, 2014-12, Vol.165 (6), p.1091-1097.e2

2014

Volltextzugriff (PDF)

Probability of Treatment Following Acute Decline in Lung Function in Children with Cystic Fibrosis is Related to Baseline Pulmonary Function

The Journal of pediatrics, 2013-10, Vol.163 (4), p.1152-1157.e2

2013

Volltextzugriff (PDF)

Socioeconomic Status and the Likelihood of Antibiotic Treatment for Signs and Symptoms of Pulmonary Exacerbation in Children with Cystic Fibrosis

The Journal of pediatrics, 2011-11, Vol.159 (5), p.819-824.e1

2011

Volltextzugriff (PDF)

Relationship between Inhaled Corticosteroid Therapy and Rate of Lung Function Decline in Children with Cystic Fibrosis

The Journal of pediatrics, 2008-12, Vol.153 (6), p.746-751.e2

2008

Volltextzugriff (PDF)

Inflammation and Anti-Inflammatory Therapies for Cystic Fibrosis

Clinics in chest medicine, 2007-06, Vol.28 (2), p.331-346

2007

Volltextzugriff (PDF)

Reply

The Journal of pediatrics, 2016, Vol.172, p.228-229

2016

Volltextzugriff (PDF)

Rapid intravenous desensitization to colistin

Annals of allergy, asthma, & immunology, 2012-11, Vol.109 (5), p.361-362

2012

Volltextzugriff (PDF)

A CFTR corrector (lumacaftor) and a CFTR potentiator (ivacaftor) for treatment of patients with cystic fibrosis who have a phe508del CFTR mutation: a phase 2 randomised controlled trial

The lancet respiratory medicine, 2014-07, Vol.2 (7), p.527-538

2014

Volltextzugriff (PDF)

Assessment of safety and efficacy of long-term treatment with combination lumacaftor and ivacaftor therapy in patients with cystic fibrosis homozygous for the F508del-CFTR mutation (PROGRESS): a phase 3, extension study

The lancet respiratory medicine, 2017-02, Vol.5 (2), p.107-118

2017

Volltextzugriff (PDF)

Long-term safety and efficacy of ivacaftor in patients with cystic fibrosis who have the Gly551Asp- CFTR mutation: a phase 3, open-label extension study (PERSIST)

The lancet respiratory medicine, 2014-11, Vol.2 (11), p.902-910

2014

Volltextzugriff (PDF)

Genetic Modifiers of Lung Disease in Cystic Fibrosis

The New England journal of medicine, 2005-10, Vol.353 (14), p.1443-1453

2005

Volltextzugriff (PDF)

Impact of Pseudomonas and Staphylococcus Infection on Inflammation and Clinical Status in Young Children with Cystic Fibrosis

The Journal of pediatrics, 2009-02, Vol.154 (2), p.183-188.e3

2009

Volltextzugriff (PDF)

Forced Expiratory Volume in 1 Second Variability Helps Identify Patients with Cystic Fibrosis at Risk of Greater Loss of Lung Function

The Journal of pediatrics, 2016-02, Vol.169, p.116-121.e2

2016

Volltextzugriff (PDF)

A two-year randomized, placebo-controlled trial of dornase alfa in young patients with cystic fibrosis with mild lung function abnormalities

The Journal of pediatrics, 2001-12, Vol.139 (6), p.813-820

2001

Volltextzugriff (PDF)

Jointly modelling the relationship between survival and pulmonary function in cystic fibrosis patients

Statistics in medicine, 2002-05, Vol.21 (9), p.1271-1287

2002

Volltextzugriff (PDF)

Epidemiologic study of cystic fibrosis: Design and implementation of a prospective, multicenter, observational study of patients with cystic fibrosis in the U.S. and Canada

Pediatric pulmonology, 1999-10, Vol.28 (4), p.231-241

1999

Volltextzugriff (PDF)

Relation of sweat chloride concentration to severity of lung disease in cystic fibrosis

Pediatric pulmonology, 2004-09, Vol.38 (3), p.204-209

2004

Volltextzugriff (PDF)

Beta 2 adrenergic receptor polymorphisms in cystic fibrosis

Pediatric pulmonology, 2005-06, Vol.39 (6), p.544-550

2005

Volltextzugriff (PDF)

Reply to: Efficacy of the Flutter device for airway mucus clearance in patients with cystic fibrosis

The Journal of pediatrics, 1996, Vol.128 (1), p.165-166

1996

Volltextzugriff (PDF)

1 – 23 von 23

Suche als RSS-Feed

Suchergebnisse filtern

Filter anzeigen

Nur zeigen

Geprüft (Peer-Review)
(23)
Mit Volltextzugriff
(22)

Publikationsform

Artikel
(23)

Sprache

Englisch
(23)

Erscheinungsjahr

n.n

Thema

Humans
(21)
Life Sciences & Biomedicine
(21)
Science & Technology
(21)
Male
(20)
Female
(19)
Child
(17)
Adolescent
(16)
Pediatrics
(13)
Cystic Fibrosis - Drug Therapy
(12)
Cystic Fibrosis - Physiopathology
(12)
Biological And Medical Sciences
(10)
Forced Expiratory Volume
(10)
Medical Sciences
(10)
Adult
(9)
Respiratory System
(9)
Cystic Fibrosis - Genetics
(7)
Cystic Fibrosis Transmembrane Conductance Regulator - Genetics
(7)
General Aspects
(7)
Lung - Physiopathology
(7)
Child, Preschool
(6)

15 weitere anzeigen...

Weniger anzeigen...

Menü

Weitere Dienste

Einstellungen

Efficacy and safety of lumacaftor/ivacaftor combination therapy in patients with cystic fibrosis homozygous for Phe508del CFTR by pulmonary function subgroup: a pooled analysis

Risk Factors For Rate of Decline in Forced Expiratory Volume in One Second in Children and Adolescents with Cystic Fibrosis

Association of Socioeconomic Status with the Use of Chronic Therapies and Healthcare Utilization in Children with Cystic Fibrosis

Improvements in Lung Function and Height among Cohorts of 6-Year-Olds with Cystic Fibrosis from 1994 to 2012

Probability of Treatment Following Acute Decline in Lung Function in Children with Cystic Fibrosis is Related to Baseline Pulmonary Function

Socioeconomic Status and the Likelihood of Antibiotic Treatment for Signs and Symptoms of Pulmonary Exacerbation in Children with Cystic Fibrosis

Relationship between Inhaled Corticosteroid Therapy and Rate of Lung Function Decline in Children with Cystic Fibrosis

Inflammation and Anti-Inflammatory Therapies for Cystic Fibrosis

Reply

Rapid intravenous desensitization to colistin

Ataluren for the treatment of nonsense-mutation cystic fibrosis: a randomised, double-blind, placebo-controlled phase 3 trial

A CFTR corrector (lumacaftor) and a CFTR potentiator (ivacaftor) for treatment of patients with cystic fibrosis who have a phe508del CFTR mutation: a phase 2 randomised controlled trial

Assessment of safety and efficacy of long-term treatment with combination lumacaftor and ivacaftor therapy in patients with cystic fibrosis homozygous for the F508del-CFTR mutation (PROGRESS): a phase 3, extension study

Long-term safety and efficacy of ivacaftor in patients with cystic fibrosis who have the Gly551Asp- CFTR mutation: a phase 3, open-label extension study (PERSIST)

Genetic Modifiers of Lung Disease in Cystic Fibrosis

Impact of Pseudomonas and Staphylococcus Infection on Inflammation and Clinical Status in Young Children with Cystic Fibrosis

Forced Expiratory Volume in 1 Second Variability Helps Identify Patients with Cystic Fibrosis at Risk of Greater Loss of Lung Function

A two-year randomized, placebo-controlled trial of dornase alfa in young patients with cystic fibrosis with mild lung function abnormalities

Jointly modelling the relationship between survival and pulmonary function in cystic fibrosis patients

Epidemiologic study of cystic fibrosis: Design and implementation of a prospective, multicenter, observational study of patients with cystic fibrosis in the U.S. and Canada

Relation of sweat chloride concentration to severity of lung disease in cystic fibrosis

Beta 2 adrenergic receptor polymorphisms in cystic fibrosis

Reply to: Efficacy of the Flutter device for airway mucus clearance in patients with cystic fibrosis

Suchergebnisse filtern